TACE with immunotherapy for unresectable liver cancer
Part of Cancer clinical trials.
This trial tests a combination treatment for liver cancer that cannot be surgically removed. It combines a procedure called TACE (which blocks blood flow to the tumor) with targeted drugs and immunotherapy (helping your immune system fight the cancer). The goal is to see if this combined approach works better and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of liver cancer (called hepatocellular carcinoma) that cannot be removed by surgery.
- You are between 18 and 68 years old.
- You have at least one liver tumor that can be seen on a scan.
- You are generally well enough to care for yourself (performance status 0 or 1).
- Your liver function is relatively good (Child-Pugh score 7 or lower, and blood tests show adequate organ function).
- You are willing to not have children during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests combining TACE (a procedure to block the tumor's blood supply) with immunotherapy drugs for liver cancer that has not spread outside the liver. It is for people who have not had any prior treatment for their liver cancer and are healthy enough for TACE.
This trial tests a combination of TACE (a procedure that blocks blood supply to the tumor) plus three immunotherapy drugs (sintilimab, bevacizumab, ipilimumab) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination works better than TACE alone.
This trial tests whether a combination of two therapies—targeted chemotherapy delivered directly to the liver (TACE) plus immunotherapy (atezolizumab) and a targeted drug (bevacizumab)—can keep liver cancer from coming back after surgery. It is for people whose tumors can be surgically removed but are at high risk of recurrence.
This trial tests a combination of two treatments for advanced liver cancer: TACE (a procedure that blocks the blood supply to the tumor) and an anti-PD-1 antibody (a type of immunotherapy that helps your immune system fight cancer). The goal is to see if this combination works better than either treatment alone and to understand how it affects the immune system around the tumor.
This trial tests whether combining TACE (a liver-targeted chemo procedure) with two medicines—an immune “checkpoint” drug and a blood-vessel blocking drug—can control unresectable hepatocellular carcinoma. It’s designed for people who can’t have surgery or curative ablation, and who still have reasonably strong liver and overall health.
This trial tests a procedure called TACE combined with an immune-boosting step for people with liver cancer that cannot be surgically removed. The goal is to see if this combination can help control the tumor while you are already on systemic treatment.
Hear when a new Unresectable Liver Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.